{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:12:34Z","timestamp":1780449154811,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>While the importance of the serotonergic system in obsessive compulsive disorder (OCD) is well established, its role in Tourette syndrome (TS) is uncertain. Particularly in TS patients with comorbid OCD (TS\u2009+\u2009OCD), decreased serotonin transporter (SERT) binding has been suggested. Here, we investigated for the first time SERT binding in TS patients with and without OCD (TS\u2009\u2212\u2009OCD) compared to both healthy controls (HC) and OCD patients as well as the influence of escitalopram using the potent SERT imaging ligand [<jats:sup>123<\/jats:sup>I]2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine ([<jats:sup>123<\/jats:sup>I]ADAM) and single-photon emission tomography (SPECT). We included 33 adult subjects (10 HC, 10 TS\u2009\u2212\u2009OCD, 8 TS\u2009+\u2009OCD and 5 OCD). In patients with OCD and TS\u2009+\u2009OCD [<jats:sup>123<\/jats:sup>I]ADAM SPECT was repeated after 12\u201316 weeks treatment with escitalopram. SERT binding was normal in patients with OCD and TS\u2009\u2212\u2009OCD, but significantly increased (p\u2009&lt;\u20090.05) in those with TS\u2009+\u2009OCD, particularly in caudate and midbrain compared to both HC and TS\u2009\u2212\u2009OCD. Treatment with escitalopram resulted in a significant overall reduction in SERT binding (range, 19 to 79%, p values between 0.0409 and &lt;0.0001) without any correlation with clinical improvement. Our results provide further evidence that alterations in the serotonergic system in TS are related to comorbid OCD and do not represent the primary cause of the disease.<\/jats:p>","DOI":"10.1038\/s41598-018-37710-4","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T11:04:42Z","timestamp":1548846282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-7419","authenticated-orcid":false,"given":"K. R.","family":"M\u00fcller-Vahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Szejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jakubovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Geworski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Berding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"37710_CR1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.51.4.1069","volume":"51","author":"A Heinz","year":"1998","unstructured":"Heinz, A. et al. Tourette\u2019s syndrome: [I-123] beta-CIT SPECT correlates of vocal tic severity. Neurology 51, 1069\u20131074 (1998).","journal-title":"Neurology"},{"key":"37710_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neulet.2005.05.031","volume":"385","author":"KR M\u00fcller-Vahl","year":"2005","unstructured":"M\u00fcller-Vahl, K. R. et al. Serotonin transporter binding in Tourette Syndrome. Neurosci. Lett. 385, 120\u2013125 (2005).","journal-title":"Neurosci. Lett."},{"key":"37710_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/sj.npp.1301528","volume":"33","author":"DF Wong","year":"2008","unstructured":"Wong, D. F. et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 33, 1239\u20131251 (2008).","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"37710_CR4","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/sj.npp.1301290","volume":"32","author":"W Zitterl","year":"2007","unstructured":"Zitterl, W. et al. [123I]-??-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology 32, 1661\u20131668 (2007).","journal-title":"Neuropsychopharmacology"},{"key":"37710_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1600-0447.2006.00940.x","volume":"115","author":"SG Hasselbalch","year":"2007","unstructured":"Hasselbalch, S. G. et al. Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder. Acta Psychiatr. Scand. 115, 388\u2013394 (2007).","journal-title":"Acta Psychiatr. Scand."},{"key":"37710_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pscychresns.2005.07.002","volume":"140","author":"S Hesse","year":"2005","unstructured":"Hesse, S. et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res. - Neuroimaging 140, 63\u201372 (2005).","journal-title":"Psychiatry Res. - Neuroimaging"},{"key":"37710_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1017\/S1461145710001604","volume":"14","author":"S Hesse","year":"2011","unstructured":"Hesse, S. et al. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 14, 606\u2013617 (2011).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"37710_CR8","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00702-007-0785-6","volume":"114","author":"M Reimold","year":"2007","unstructured":"Reimold, M. et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - A [11C]DASB PET study. J. Neural Transm. 114, 1603\u20131609 (2007).","journal-title":"J. Neural Transm."},{"key":"37710_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuroimage.2009.07.069","volume":"49","author":"R Matsumoto","year":"2010","unstructured":"Matsumoto, R. et al. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: A [11C]DASB PET study. Neuroimage 49, 121\u2013126 (2010).","journal-title":"Neuroimage"},{"key":"37710_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1017\/S0033291715001865","volume":"46","author":"E Kim","year":"2016","unstructured":"Kim, E. et al. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study. Psychol. Med. 46, 357\u2013366 (2016).","journal-title":"Psychol. Med."},{"key":"37710_CR11","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/S0006-3223(03)00544-4","volume":"54","author":"HB Simpson","year":"2003","unstructured":"Simpson, H. B. et al. Serotonin transporters in obsessive-compulsive disorder: A positron emission tomography study with [11C]McN 5652. Biol. Psychiatry 54, 1414\u20131421 (2003).","journal-title":"Biol. Psychiatry"},{"key":"37710_CR12","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1176\/appi.ajp.161.12.2201","volume":"161","author":"NJ Van Der Wee","year":"2004","unstructured":"Van Der Wee, N. J. et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]\u03b2-CIT SPECT. Am. J. Psychiatry 161, 2201\u20132206 (2004).","journal-title":"Am. J. Psychiatry"},{"key":"37710_CR13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0006-3223(03)00183-5","volume":"54","author":"O Pogarell","year":"2003","unstructured":"Pogarell, O. et al. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol. Psychiatry 54, 1406\u20131413 (2003).","journal-title":"Biol. Psychiatry"},{"key":"37710_CR14","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1038\/npp.2008.35","volume":"33","author":"W Zitterl","year":"2008","unstructured":"Zitterl, W. et al. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology 33, 3126\u201334 (2008).","journal-title":"Neuropsychopharmacology"},{"key":"37710_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000090702","volume":"53","author":"K Stengler-Wenzke","year":"2006","unstructured":"Stengler-Wenzke, K. et al. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder. Neuropsychobiology 53, 40\u201345 (2006).","journal-title":"Neuropsychobiology"},{"key":"37710_CR16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/jcbfm.2014.82","volume":"34","author":"G Gryglewski","year":"2014","unstructured":"Gryglewski, G., Lanzenberger, R., Kranz, G. S. & Cumming, P. Meta-analysis of molecular imaging of serotonin transporters in major depression. Journal of Cerebral Blood Flow and Metabolism 34, 1096\u20131103 (2014).","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"37710_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00406-004-0520-3","volume":"254","author":"E Maron","year":"2004","unstructured":"Maron, E. et al. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. Eur. Arch. Psychiatry Clin. Neurosci. 254, 392\u2013396 (2004).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"37710_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2967\/jnumed.107.045518","volume":"49","author":"NJ van der Wee","year":"2008","unstructured":"van der Wee, N. J. et al. Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT. J. Nucl. Med. 49, 757\u2013763 (2008).","journal-title":"J. Nucl. Med."},{"key":"37710_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0969-8051(00)00084-6","volume":"27","author":"S Oya","year":"2000","unstructured":"Oya, S. et al. 2-((2-((Dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): An improved serotonin transporter ligand. Nucl. Med. Biol. 27, 249\u2013254 (2000).","journal-title":"Nucl. Med. Biol."},{"key":"37710_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.nucmedbio.2005.10.006","volume":"33","author":"K-J Lin","year":"2006","unstructured":"Lin, K.-J. et al. Brain SPECT imaging and whole-body biodistribution with [(123)I]ADAM - a serotonin transporter radiotracer in healthy human subjects. Nucl. Med. Biol. 33, 193\u2013202 (2006).","journal-title":"Nucl. Med. Biol."},{"key":"37710_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ana.410060109","volume":"6","author":"IJ Butler","year":"1979","unstructured":"Butler, I. J., Koslow, S. H., Seifert, W. E., Caprioli, R. M. & Singer, H. S. Biogenic amine metabolism in tourette syndrome. Ann. Neurol. 6, 37\u201339 (1979).","journal-title":"Ann. Neurol."},{"key":"37710_CR22","first-page":"177","volume":"35","author":"HS Singer","year":"1982","unstructured":"Singer, H. S., Tune, L. E., Butler, I. J., Zaczek, R. & Coyle, J. T. Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette syndrome. Adv. Neurol. 35, 177\u2013183 (1982).","journal-title":"Adv. Neurol."},{"key":"37710_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/archpsyc.1992.01820070078016","volume":"49","author":"GM Anderson","year":"1992","unstructured":"Anderson, G. M. et al. Brain Monoamines and Amino Acids in Gilles de la Tourette\u2019s Syndrome: A Preliminary Study of Subcortical Regions. Archives of General Psychiatry 49, 584\u2013586 (1992).","journal-title":"Archives of General Psychiatry"},{"key":"37710_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajmg.1320360410","volume":"36","author":"DE Comings","year":"1990","unstructured":"Comings, D. E. Blood serotonin and tryptophan in Tourette syndrome. Am. J. Med. Genet. 36, 418\u2013430 (1990).","journal-title":"Am. J. Med. Genet."},{"key":"37710_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ana.410270415","volume":"27","author":"HS Singer","year":"1990","unstructured":"Singer, H. S., Hahn, I. H., Krowiak, E., Nelson, E. & Moran, T. Tourette\u2019s syndrome: a neurochemical analysis of postmortem cortical brain tissue. Ann. Neurol. 27, 443\u2013446 (1990).","journal-title":"Ann. Neurol."},{"key":"37710_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jns.2003.12.006","volume":"219","author":"K Minzer","year":"2004","unstructured":"Minzer, K., Lee, O., Hong, J. J. & Singer, H. S. Increased prefrontal D2 protein in Tourette syndrome: A postmortem analysis of frontal cortex and striatum. J. Neurol. Sci. 219, 55\u201361 (2004).","journal-title":"J. Neurol. Sci."},{"key":"37710_CR27","doi-asserted-by":"crossref","unstructured":"Qi, Y., Zheng, Y., Li, Z. & Xiong, L. Progress in genetic studies of tourette\u2019s syndrome. Brain Sciences 7 (2017).","DOI":"10.3390\/brainsci7100134"},{"key":"37710_CR28","doi-asserted-by":"publisher","unstructured":"Abdulkadir, M. et al. Investigation of previously implicated genetic variants in chronic tic disorders: a transmission disequilibrium test approach. European Archives of Psychiatry and Clinical Neuroscience 1\u201316, https:\/\/doi.org\/10.1007\/s00406-017-0808-8 (2017).","DOI":"10.1007\/s00406-017-0808-8"},{"key":"37710_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1017\/S1461145706006559","volume":"10","author":"S Haugbol","year":"2007","unstructured":"Haugbol, S. et al. Cerebral 5-HT2A receptor binding is increased in patients with Tourette\u2019s syndrome. Int J Neuropsychopharmacol 10, 245\u2013252 (2007).","journal-title":"Int J Neuropsychopharmacol"},{"key":"37710_CR30","first-page":"123","volume":"58","author":"GM Anderson","year":"1992","unstructured":"Anderson, G. M. et al. Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Adv. Neurol. 58, 123\u2013133 (1992).","journal-title":"Adv. Neurol."},{"key":"37710_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12149-014-0815-z","volume":"28","author":"YS Lee","year":"2014","unstructured":"Lee, Y. S. et al. Performance measurement of PSF modeling reconstruction (True X) on Siemens Biograph TruePoint TrueV PET\/CT. Ann. Nucl. Med. 28, 340\u2013348 (2014).","journal-title":"Ann. Nucl. Med."},{"key":"37710_CR32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4103\/0028-3886.68663","volume":"58","author":"L Jijun","year":"2010","unstructured":"Jijun, L. et al. Abnormal expression of dopamine and serotonin transporters associated with the pathophysiologic mechanism of Tourette syndrome. Neurol. India 58, 523\u2013529 (2010).","journal-title":"Neurol. India"},{"key":"37710_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/sj.npp.1300036","volume":"28","author":"A Kugaya","year":"2003","unstructured":"Kugaya, A. et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 28, 413\u2013420 (2003).","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"37710_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/cap.1997.7.75","volume":"7","author":"L SCAHILL","year":"1997","unstructured":"SCAHILL, L. et al. Fluoxetine Has No Marked Effect on Tic Symptoms in Patients with Tourette\u2019s Syndrome: A Double-Blind Placebo-Controlled Study. J. Child Adolesc. Psychopharmacol. 7, 75\u201385 (1997).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"37710_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2967\/jnumed.107.046102","volume":"49","author":"VG Frokjaer","year":"2008","unstructured":"Frokjaer, V. G. et al. Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans. J. Nucl. Med. 49, 247\u2013254 (2008).","journal-title":"J. Nucl. Med."},{"key":"37710_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.zemedi.2011.04.007","volume":"22","author":"P Knoll","year":"2012","unstructured":"Knoll, P. et al. Comparison of advanced iterative reconstruction methods for SPECT\/CT. Z. Med. Phys. 22, 58\u201369 (2012).","journal-title":"Z. Med. Phys."},{"key":"37710_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ana.410310113","volume":"31","author":"GJ Harris","year":"1992","unstructured":"Harris, G. J. et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington\u2019s disease. Ann. Neurol. 31, 69\u201375 (1992).","journal-title":"Ann. Neurol."},{"key":"37710_CR38","first-page":"425","volume":"6","author":"PR Koehler","year":"1985","unstructured":"Koehler, P. R. et al. MR measurement of normal and pathologic brainstem diameters. Am. J. Neuroradiol. 6, 425\u2013427 (1985).","journal-title":"Am. J. Neuroradiol."},{"key":"37710_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1055\/s-2008-1081457","volume":"39","author":"NMM Mol Debes","year":"2008","unstructured":"Mol Debes, N. M. M., Hjalgrim, H. & Skov, L. Limited knowledge of Tourette syndrome causes delay in diagnosis. Neuropediatrics 39, 101\u2013105 (2008).","journal-title":"Neuropediatrics"},{"key":"37710_CR40","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1088\/0031-9155\/47\/8\/302","volume":"47","author":"BO Knoop","year":"2002","unstructured":"Knoop, B. O., Geworski, L., Hofmann, M., Munz, D. L. & Knapp, W. H. Use of recovery coefficient as a test of system linearity of response in positron emission tomography (PET). Physics in Medicine and Biology 47, 1237\u20131254 (2002).","journal-title":"Physics in Medicine and Biology"},{"key":"37710_CR41","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/mds.20112","volume":"19","author":"AM Catafau","year":"2004","unstructured":"Catafau, A. M. et al. Impact of dopamine transporter SPECT using123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov. Disord. 19, 1175\u20131182 (2004).","journal-title":"Mov. Disord."},{"key":"37710_CR42","first-page":"1301","volume":"46","author":"AM Catafau","year":"2005","unstructured":"Catafau, A. M., P\u00e9rez, V., Penengo, M. M. & Al., E. SPECT of Serotonin Transporters Using 123 I-ADAM: Optimal Imaging Time After Bolus Injection and Long-Term Test \u2013 Retest in Healthy Volunteers. J Nucl Med 46, 1301\u20131310 (2005).","journal-title":"J Nucl Med"},{"key":"37710_CR43","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1055\/s-0038-1623914","volume":"43","author":"JT Kuikka","year":"2004","unstructured":"Kuikka, J. T. Quantitative accuracy of serotonergic neurotransmission imaging with high-resolution 123I SPECT. NuklearMedizin 43, 185\u2013189 (2004).","journal-title":"NuklearMedizin"},{"key":"37710_CR44","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/00004583-198907000-00015","volume":"28","author":"JF LECKMAN","year":"1989","unstructured":"LECKMAN, J. F. et al. The Yale Global Tic Severity Scale: Initial Testing of a Clinician-Rated Scale of Tic Severity. J. Am. Acad. Child Adolesc. Psychiatry 28, 566\u2013573 (1989).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"37710_CR45","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman, W. K. et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability. Arch. Gen. Psychiatry 46, 1006\u20131011 (1989).","journal-title":"Arch. Gen. Psychiatry"},{"key":"37710_CR46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. & Erbaugh, J. An Inventory for Measuring Depression. Arch. Gen. Psychiatry 4, 561\u2013571 (1961).","journal-title":"Arch. Gen. Psychiatry"},{"key":"37710_CR47","unstructured":"Laux, L., Glanzmann, P., Schaffner, P. & Spielberger, C. Das State-Trait-Angstinventar: STAI. Weinheim: Beltz (1981)."},{"key":"37710_CR48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eurpsy.2009.12.024","volume":"26","author":"H Christiansen","year":"2011","unstructured":"Christiansen, H. et al. German validation of the Conners Adult ADHD Rating Scales-self-report (CAARS-S) I: Factor structure and normative data. Eur. Psychiatry 26, 100\u2013107 (2011).","journal-title":"Eur. Psychiatry"},{"key":"37710_CR49","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s00115-001-1215-x","volume":"73","author":"P Retz-Junginger","year":"2002","unstructured":"Retz-Junginger, P. et al. Wender Utah rating scale. The short-version for the assessment of the attention-deficit hyperactivity disorder in adults. Nervenarzt 73, 830\u2013838 (2002).","journal-title":"Nervenarzt"},{"key":"37710_CR50","first-page":"13","volume":"9","author":"LR Derogatis","year":"1973","unstructured":"Derogatis, L. R., Lipman, R. S. & Covi, L. The SCL-90: An outpatient psychiatric rating scale. Psychopharmacol. Bull. 9, 13\u201328 (1973).","journal-title":"Psychopharmacol. Bull."},{"key":"37710_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1600-0404.1995.tb07018.x","volume":"91","author":"S Lehrl","year":"1995","unstructured":"Lehrl, S., Triebig, G. & Fischer, B. Multiple choice vocabulary test MWT as a valid and short test to estimate premorbid intelligence. Acta Neurol. Scand. 91, 335\u2013345 (1995).","journal-title":"Acta Neurol. Scand."}],"updated-by":[{"DOI":"10.1038\/s41598-020-68278-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37710-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37710-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37710-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T05:11:46Z","timestamp":1671253906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37710-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["37710"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-37710-4","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-020-68278-7","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"25 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"972"}}